The Median Effective Concentration (EC50) of Alfentanil Combined with Propofol Closed-Loop Targeted Infusion in Super-Elderly Patients Undergoing Endoscopic Retrograde Cholangiopancreatography (ERCP)
Drug Design, Development and Therapy · 2025
DOI: 10.2147/dddt.s520421 ↗Kurz gefasst
Klinische Studie in der Zeitschrift Drug Design, Development and Therapy, 2025. Verfasst von Zenggang Sun und 4 weiteren Autor:innen. Beteiligte Einrichtung: School of Anesthesiology, Shandong Second Medical University, Weifang, Shandong Province, 261053, People's Republic of China. Hauptthemen laut MEDLINE: Alfentanil, Anesthetics, Intravenous, Cholangiopancreatography, Endoscopic Retrograde, Propofol. Die Arbeit nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Purpose
To investigate the median effective concentration (EC50) of alfentanil combined with propofol closed-loop targeted infusion when used for sedation in super-elderly endoscopic retrograde cholangiopancreatography (ERCP) patients. Patients and Methods: A total of 28 super-elderly patients (>85 years old) undergoing elective ERCP from April to September 2024 were enrolled to receive target-controlled continuous infusion of alfentanil with an initial infusion concentration of 50ng/mL, and the continuous infusion concentration was determined according to the Dixon up and down method, and the incremental/decremental gradient of alfentanil was set at 10ng/mL. The observation was terminated after 8 reflexes. The EC50 of target-controlled infusion of alfentanil combined with propofol in the operation of ERCP in super-aged patients was calculated. HR and MAP were recorded at the time of entering the room at rest (T0), after anesthesia induction (T1), before duodenoscope placement (T2), and within 3 minutes after duodenoscope placement (T3).
Results
In this study, the EC50 of alfentanil combined with propofol target-controlled infusion during ERCP in super-elderly patients was determined to be 36.52ng/mL (95% confidence interval [CI]: 32.12-41.71ng/mL). Among the 28 patients, 27 patients (96.43%) had a change in HR less than 20% of baseline during duodenoscopy, and 1 patient (3.57%) had a change in HR more than 20% of baseline during duodenoscopy. Of the 28 patients, 26 (92.86%) had a MAP change of less than 20% of baseline during duodenoscopy, and 2 (7.14%) had a MAP change of more than 20% of baseline.
Conclusion
The EC50 of alfentanil combined with propofol by closed-loop target-controlled infusion during ERCP in super-elderly patients is 36.52ng/mL. At this concentration level, the patients can be satisfied with surgical anesthesia and maintain relatively stable hemodynamics.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Anesthesiology, Shandong Second Medical University, Weifang, Shandong Province, 261053, People's Republic of China.
- Department of Anesthesiology, Weifang People's Hospital, Weifang, Shandong Province, 261041, People's Republic of China.
Zitieren
APA
Sun, Z., Li, W., Zhong, Y., Lang, B., & Luo, Y. (2025). The Median Effective Concentration (EC50) of Alfentanil Combined with Propofol Closed-Loop Targeted Infusion in Super-Elderly Patients Undergoing Endoscopic Retrograde Cholangiopancreatography (ERCP). Drug Design, Development and Therapy. https://doi.org/10.2147/dddt.s520421
Vancouver
Sun Z, Li W, Zhong Y, Lang B, Luo Y. The Median Effective Concentration (EC50) of Alfentanil Combined with Propofol Closed-Loop Targeted Infusion in Super-Elderly Patients Undergoing Endoscopic Retrograde Cholangiopancreatography (ERCP). Drug Design, Development and Therapy. 2025. doi:10.2147/dddt.s520421
BibTeX
@article{Sun2025,
author = {Sun, Zenggang and Li, Weiqiang and Zhong, Yuqi and Lang, Bao and Luo, Yanhua},
title = {The Median Effective Concentration (EC50) of Alfentanil Combined with Propofol Closed-Loop Targeted Infusion in Super-Elderly Patients Undergoing Endoscopic Retrograde Cholangiopancreatography (ERCP)},
journal = {Drug Design, Development and Therapy},
year = {2025},
doi = {10.2147/dddt.s520421}
}
EUVIMED